All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Key communications on GvHD at EHA 2021

During the EHA2021 Virtual Congress, the GvHD Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, What were the key communications on GvHD at EHA 2021?

Key communications on GvHD at EHA 2021

In this video, Mohty highlights two key presentations from EHA 2021. The first one being the phase III INTEGRATE trial of ibrutinib combined with corticosteroids in previously untreated patients with chronic GvHD. While the second communication was a subgroup analysis of the REACH2 trial evaluating the efficacy and safety of ruxolitinib in patients with steroid-refractory acute GvHD who crossed over from the best alternative treatment.